Overview

Pulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy Trial in Japan

Status:
Completed
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
Objective: Determine the safety and efficacy of GM-CSF inhalation in patients with aPAP. Study Design: multi-center, randomized, double-blind, placebo- controlled, safety/efficacy study.
Phase:
Phase 2
Details
Lead Sponsor:
Niigata University Medical & Dental Hospital
Treatments:
Sargramostim